orforglipron: Clinical Trials

27 trials of orforglipron, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

10 completed, 8 active not recruiting, 8 recruiting, 1 not yet recruiting. 27 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 327Completed 10, Active not recruiting 8, Recruiting 8, Not yet recruiting 1

Follow orforglipron: new trials by email Literature Review of orforglipron trials Research Report on orforglipron

Trials (filtered) newest first · largest first

All 27 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study of Orforglipron (LY3502970) in Chinese Participants With Obesity or Overweight and Weight-Related Health Problems
Orforglipron, Placebo - Obesity, Overweight
Phase 3Not yet recruitingEli Lilly and Company1922026-12-012026-10-13
A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity
Orforglipron, Placebo - Overweight, Prediabetic State
Phase 3RecruitingEli Lilly and Company20012026-08-262026-11-05
A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Who Observe Ramadan Fasting
Orforglipron - Diabetes Mellitus, Type 2, Diabetes Melletus
Phase 3RecruitingEli Lilly and Company1302026-07-152026-10-08
A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 Diabetes
Orforglipron, Dulaglutide - Diabetes Mellitus, Type 2
Phase 3RecruitingEli Lilly and Company1702026-07-082026-11-05
A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)
Orforglipron, Placebo - Atherosclerosis Cardiovascular Disease, Chronic Kidney Disease
Phase 3RecruitingEli Lilly and Company71402025-12-012026-11-04
Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease
Orforglipron, Placebo - Peripheral Arterial Disease
Phase 3RecruitingEli Lilly and Company12052025-10-312026-11-04
A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight
Orforglipron, Placebo - Urinary Incontinence,Stress
Phase 3RecruitingEli Lilly and Company10002025-09-302026-11-04
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee
Orforglipron, Placebo - Osteoarthritis
Phase 3Active not recruitingEli Lilly and Company8002025-09-152026-10-08
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes
Orforglipron, Placebo - Obesity, Overweight
Phase 3Active not recruitingEli Lilly and Company6002025-05-192026-04-20
A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes
Orforglipron, Placebo - Obesity, Overweight
Phase 3Active not recruitingEli Lilly and Company14002025-05-152026-07-31
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity
Orforglipron, Placebo - Obesity, Overweight
Phase 3Active not recruitingEli Lilly and Company8002025-05-152026-07-29
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1
Orforglipron, Placebo - Hypertension, Overweight or Obesity
Phase 3Active not recruitingEli Lilly and Company4872025-04-302026-05-29
A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)
Orforglipron, Placebo - Hypertension
Phase 3Active not recruitingEli Lilly and Company9742025-04-302026-05-29
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2
Orforglipron, Placebo - Hypertension
Phase 3Active not recruitingEli Lilly and Company4872025-04-302026-05-29
A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities
Orforglipron, Placebo - Obesity, Overweight
Phase 3RecruitingEli Lilly and Company1502024-11-182026-11-04
A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
Orforglipron, Placebo - Obesity, Overweight
Phase 3RecruitingEli Lilly and Company1252024-11-182026-11-04
A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or Overweight
Orforglipron, Placebo - OSA, Overweight or Obesity
Phase 3CompletedEli Lilly and Company7122024-10-222026-09-14
A Study of Orforglipron for the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-MAINTAIN)
Orforglipron, Placebo - Obesity, Overweight
Phase 3CompletedEli Lilly and Company3762024-09-132026-06-04
A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin
Orforglipron, Dapagliflozin - Type 2 Diabetes
Phase 3CompletedEli Lilly and Company9622024-01-102026-10-16
A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Without Metformin and/or SGLT-2 Inhibitor
Orforglipron, Placebo - Type 2 Diabetes
Phase 3CompletedEli Lilly and Company5462023-11-102026-10-01

Showing 20 of 27. Sign in to see all of them.

Conditions studied

Obesity (14)  ·  Overweight (14)  ·  Diabetes Mellitus, Type 2 (11)  ·  Hypertension (3)  ·  Nutrition Disorders (2)  ·  Renal Insufficiency, Chronic (2)  ·  Arthritis (1)  ·  Behavior (1)  ·  Body Weight Changes (1)  ·  Cardiovascular Diseases (1)  ·  Endocrine System Diseases (1)  ·  Fasting (1)  ·  Feeding Behavior (1)  ·  Glucose Metabolism Disorders (1)  ·  Heart Diseases (1)

Sponsors

Eli Lilly and Company (27)

Countries

United States (22)  ·  Japan (21)  ·  China (20)  ·  Puerto Rico (15)  ·  Argentina (13)  ·  Germany (13)  ·  Czechia (12)  ·  India (12)  ·  Mexico (11)  ·  Spain (10)  ·  Brazil (9)  ·  Poland (9)  ·  South Korea (9)  ·  Greece (7)  ·  Taiwan (7)

Results publications

PMID 42577069, PMID 40544435, PMID 40960239, PMID 41275875, PMID 41765029, PMID 42120723, PMID 42251769, PMID 42259339, PMID 42383207, PMID 42607698, PMID 42750540, PMID 42815506, PMID 42830762

NIH funding

2025 (8), 2023 (2)